E. Invernizzi

Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression

E. Clementi, E. Lucenteforte, M. Nobile, 2021, Psychological Medicine.

Assessment and correlates of autistic symptoms in Schizophrenia Spectrum Disorders measured with the PANSS Autism Severity Score: A systematic review

A. Vita, G. Deste, I. Calzavara-Pinton, 2022, Frontiers in Psychiatry.

Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study

A. Vita, G. Deste, P. Valsecchi, 2022, Schizophrenia Research.

Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

E. Clementi, S. Radice, C. Scavone, 2020, BioDrugs.

Beta‐blocker‐associated hypoglycaemia: New insights from a real‐world pharmacovigilance study

E. Clementi, V. Fabiano, G. Zuccotti, 2021, British journal of clinical pharmacology.

Clinical outcome and olanzapine plasma levels in acute schizophrenia

F. Barale, M. Mauri, E. Invernizzi, 2005, European Psychiatry.

Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review

E. Clementi, S. Radice, C. Scavone, 2021, The international journal of neuropsychopharmacology.

Is there an association between inflammatory/anti-oxidant markers and the presence of psychotic symptoms or severity of illness in mood and psychotic disorders? A multi-centric study on a drug-free sample

M. Buoli, C. M. Esposito, M. Clerici, 2022, Brain, behavior, & immunity - health.